Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants

被引:106
作者
Aubert, G
Hassan-Walker, AF
Madrigal, JA
Emery, VC
Morte, C
Grace, S
Koh, MBC
Potter, M
Prentice, HG
Dodi, IA
Travers, PJ
机构
[1] UCL Royal Free & Univ Coll Med Sch, Dept Haematol, Anthony Nolan Res Inst, London NW3 2QG, England
[2] UCL Royal Free & Univ Coll Med Sch, Dept Virol, London NW3 2QG, England
[3] UCL Royal Free & Univ Coll Med Sch, Dept Haematol, London NW3 2QG, England
关键词
D O I
10.1086/323354
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immune suppression inherent in allogeneic stem cell transplantation (SCT) offers a favorable environment for infection by opportunistic agents, such as human cytomegalovirus (CMV). Despite the application of potent antiviral prophylaxis, patients remain at risk for CMV infection until adequate immunity is restored. CMV-specific CD8(+) T cell counts were monitored, using HLA-A2 tetrameric complexes, to establish the level of immune response to the viral phosphoprotein UL83 in patients after allogeneic SCT. Correlating this with viral replication and clinical status shows that the level of tetramer-positive T cells provides an assessment of CMV immune reconstitution after stem cell transplantation. Most patients with seropositive donors did reconstitute long-term CMV immunity, unless prolonged immunosuppression to control graft-versus-host disease was induced. Together with polymerase chain reaction testing, this technique provides measurable parameters that can be a guide to therapeutic decision making and can form the basis of CMV immunotherapy.
引用
收藏
页码:955 / 963
页数:9
相关论文
共 36 条
[11]   Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease [J].
Gor, D ;
Sabin, C ;
Prentice, HG ;
Vyas, N ;
Man, S ;
Griffiths, PD ;
Emery, VC .
BONE MARROW TRANSPLANTATION, 1998, 21 (06) :597-605
[12]  
GROB JP, 1987, LANCET, V1, P774
[13]   CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells [J].
Hale, G ;
Jacobs, P ;
Wood, L ;
Fibbe, WE ;
Barge, R ;
Novitzky, N ;
du Toit, C ;
Abrahams, L ;
Thomas, V ;
Bunjes, D ;
Duncker, C ;
Wiesneth, M ;
Selleslag, D ;
Hidajat, M ;
Starobinski, M ;
Bird, P ;
Waldmann, H .
BONE MARROW TRANSPLANTATION, 2000, 26 (01) :69-76
[14]  
Hassan-Walker AF, 1999, J MED VIROL, V58, P182, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt
[15]  
182::AID-JMV14&gt
[16]  
3.0.CO
[17]  
2-Q
[18]  
HERTENSTEIN B, 1995, BONE MARROW TRANSPL, V15, P387
[19]   PROVISION OF PROGNOSTIC INFORMATION IN IMMUNOCOMPROMISED PATIENTS BY ROUTINE APPLICATION OF THE POLYMERASE CHAIN-REACTION FOR CYTOMEGALOVIRUS [J].
KIDD, IM ;
FOX, JC ;
PILLAY, D ;
CHARMAN, H ;
GRIFFITHS, PD ;
EMERY, VC .
TRANSPLANTATION, 1993, 56 (04) :867-871
[20]  
KNOX KK, 1994, LANCET, V343, P1647, DOI 10.1016/S0140-6736(94)93105-4